Experienced in IgG4-Related Disease

Dr. Edward R. Broun

Hematology Oncology | Hematology | Oncology
Oncology Hematology Care Inc
4777 E Galbraith Rd, Suite 1, 
Cincinnati, OH 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
44 Years of Experience
Experienced in IgG4-Related Disease
Oncology Hematology Care Inc
4777 E Galbraith Rd, Suite 1, 
Cincinnati, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Edward Broun is a Hematologist Oncology specialist and a Hematologist in Cincinnati, Ohio. Dr. Broun has been practicing medicine for over 44 years and is rated as an Experienced provider by MediFind in the treatment of IgG4-Related Disease. His top areas of expertise are Acute Myeloid Leukemia (AML), Small Lymphocytic Lymphoma (SLL), Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Broun is currently accepting new patients.

His clinical research consists of co-authoring 5 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
1982
Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in KY
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

ONCOLOGY HEMATOLOGY CARE INC
4777 E Galbraith Rd, Suite 1, Cincinnati, OH 45236

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Enrollment Status: Recruiting
Publish Date: November 24, 2025
Intervention Type: Drug
A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase
A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase
Enrollment Status: Active_not_recruiting
Publish Date: November 21, 2025
Intervention Type: Drug
Study Drugs: Imatinib, Nilotinib, Bosutinib, Dasatinib, Asciminib
Study Phase: Phase 3
An Open Label, Multi-center Phase IIIb Study of Asciminib (ABL001) Monotherapy in Previously Treated Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
An Open Label, Multi-center Phase IIIb Study of Asciminib (ABL001) Monotherapy in Previously Treated Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
Enrollment Status: Completed
Publish Date: October 16, 2025
Intervention Type: Drug
Study Drug: ABL001
Study Phase: Phase 3
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications
Enrollment Status: Completed
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drug: KPT-8602
Study Phase: Phase 1/Phase 2
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug, Other, Procedure
Study Drugs: Clofarabine, Daunorubicin, Cytarabine, Decitabine
Study Phase: Phase 3
View 4 Less Clinical Trials

5 Total Publications

A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.
A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.
Journal: Hematological oncology
Published: January 31, 2024
Similar Doctors
Experienced in IgG4-Related Disease
Dr. Akash Mukherjee
Hematology Oncology | Hematology | Oncology
Experienced in IgG4-Related Disease
Dr. Akash Mukherjee
Hematology Oncology | Hematology | Oncology

Oncology Hematology Care Inc

4725 E Galbraith Rd, Suite 320, 
Cincinnati, OH 
 (0.1 miles away)
513-793-6052
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Akash Mukherjee is a Hematologist Oncology specialist and a Hematologist in Cincinnati, Ohio. Dr. Mukherjee is rated as a Distinguished provider by MediFind in the treatment of IgG4-Related Disease. His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Chronic Myelomonocytic Leukemia (CMML), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Mukherjee is currently accepting new patients.

Experienced in IgG4-Related Disease
Dr. Kruti S. Patel
Hematology Oncology | Hematology | Oncology
Experienced in IgG4-Related Disease
Dr. Kruti S. Patel
Hematology Oncology | Hematology | Oncology

Oncology Hematology Care Inc

4777 E Galbraith Rd, Suite 1, 
Cincinnati, OH 
 (0.1 miles away)
513-751-2273
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients

Kruti Patel is a Hematologist Oncology specialist and a Hematologist in Cincinnati, Ohio. Dr. Patel is rated as a Distinguished provider by MediFind in the treatment of IgG4-Related Disease. Her top areas of expertise are Multiple Myeloma, Myelodysplastic Syndrome (MDS), Acute Myeloblastic Leukemia without Maturation, Acute Myeloid Leukemia (AML), and Bone Marrow Aspiration. Dr. Patel is currently accepting new patients.

Experienced in IgG4-Related Disease
Dr. Evan Z. Lang
Hematology Oncology | Oncology
Experienced in IgG4-Related Disease
Dr. Evan Z. Lang
Hematology Oncology | Oncology

Oncology Hematology Care Inc

3050 Mack Rd, Suite 300, 
Fairfield, OH 
 (10.4 miles away)
513-682-4800
Languages Spoken:
English, Mandarin
See accepted insurances
Accepting New Patients

Evan Lang is a Hematologist Oncology specialist and an Oncologist in Fairfield, Ohio. Dr. Lang is rated as a Distinguished provider by MediFind in the treatment of IgG4-Related Disease. His top areas of expertise are Plummer-Vinson Syndrome, Pleuropulmonary Blastoma, Lung Cancer, Familial Colorectal Cancer, and Bone Marrow Aspiration. Dr. Lang is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Broun's expertise for a condition
ConditionClose
    View All 10 Distinguished Conditions
    View All 27 Advanced Conditions
    View All 69 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile